Advances in the treatment of advanced oestrogen-receptor-positive breast cancer

The Lancet

Volumn 389, Issue 10087, 2017, Pages 2403-2414

  Turner, Nicholas C ^a   Neven, Patrick ^b   Loibl, Sibylle ^c,d   Andre, Fabrice ^e  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c c/o GBG Forschungs GmbH ^*  (Germany)

^d Centre for Haematology and Oncology   (Germany)

^e Universite Paris Sud   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABEMACICLIB; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PALBOCICLIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RIBOCICLIB; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; ESTROGEN RECEPTOR; MTOR PROTEIN, HUMAN; NUCLEAR PROTEIN; PI3KCA PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR;

ADVANCED CANCER; ANOREXIA; BACTERIAL PNEUMONIA; BONE MARROW SUPPRESSION; CANCER HORMONE THERAPY; CANCER RESISTANCE; CLINICAL STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ENZYME INHIBITION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; HISTORY; HUMAN; INFECTION; NEUTROPENIA; NONINFECTIOUS PNEUMONITIS; PNEUMOCYSTOSIS; PNEUMONIA; PRIORITY JOURNAL; RASH; REVIEW; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CHEMISTRY; FEMALE; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; PIPERAZINES; PYRIDINES; RECEPTORS, ESTROGEN; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS;

EID: 85007574341     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)32419-9     Document Type: Review

References (103)

1. Early Breast Cancer Trialists' Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386 (2015), 1341–1352.
2. Shou, J, Massarweh, S, Osborne, CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2–positive breast cancer. J Natl Cancer Inst 96 (2004), 926–935.
3. Osborne, CK, Neven, P, Dirix, LY, et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 17 (2011), 1147–1159.
4. Robertson, JF, Ferrero, JM, Bourgeois, H, et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol 14 (2013), 228–235.
5. Chandarlapaty S, Sung P, He W, et al. cfDNA analysis from BOLERO-2 plasma samples identifies a high rate of ESR1 mutations: exploratory analysis for prognostic and predictive correlation of mutations reveals different efficacy outcomes of endocrine therapy-based regimens. San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 8–12, 2015. Abstract S2-07.
6. Fribbens, C, O'Leary, B, Kilburn, L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol 34 (2016), 2961–2968.
7. Robinson, DR, Wu, YM, Vats, P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 45 (2013), 1446–1451.
8. Baselga, J, Campone, M, Piccart, M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366 (2012), 520–529.
9. Turner, NC, Ro, J, Andre, F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373 (2015), 209–219.
10. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490 (2012), 61–70.
11. Di Leo, A, Jerusalem, G, Petruzelka, L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28 (2010), 4594–4600.
12. Ellis, MJ, Llombart-Cussac, A, Feltl, D, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol 33 (2015), 3781–3787.
13. Robertson, JF, Llombart-Cussac, A, Rolski, J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 27 (2009), 4530–4535.
14. Ellis MJ, Bondarenko I, Trishkina E, et al. FALCON: a phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer. European Society of Medical Oncology 2016 Congress; Copenhagen, Denmark; Oct 7–11, 2016. Abstract LBA14.
15. Toy, W, Shen, Y, Won, H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45 (2013), 1439–1445.
16. Schiavon, G, Hrebien, S, Garcia-Murillas, I, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med, 7, 2015, 313ra182.
17. Dickler, M, Bardia, A, Mayer, I, et al. A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with estrogen receptor+ HER2–, advanced/metastatic breast cancer. Cancer Research, 75(suppl), 2015, CT231 (abstr).
18. Sherr, CJ, Beach, D, Shapiro, GI, Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov 6 (2016), 353–367.
19. Santamaria, D, Ortega, S, Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Front Biosci 11 (2006), 1164–1188.
20. Harper, JV, Brooks, G, The mammalian cell cycle: an overview. Methods Mol Biol 296 (2005), 113–153.
21. Dickson, MA, Schwartz, GK, Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 16 (2009), 36–43.
22. Finn, RS, Dering, J, Conklin, D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res, 11, 2009, R77.
23. Warenius, HM, Kilburn, JD, Essex, JW, et al. Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of cyclin dependent kinase 4. Mol Cancer, 10, 2011, 72.
24. Miller, TW, Balko, JM, Fox, EM, et al. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 1 (2011), 338–351.
25. Finn, RS, Crown, JP, Lang, I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16 (2015), 25–35.
26. Finn, R, Martin, M, Rugo, H, et al. PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). J Clin Oncol, 34(suppl), 2016, 507 (abstr).
27. Hortobagyi, GN, Stemmer, SM, Burris, HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375 (2016), 1738–1748.
28. Dickler, M, Tolaney, S, Rugo, H, et al. MONARCH1: results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2– breast cancer, after chemotherapy for advanced disease. J Clin Oncol, 34(suppl), 2016, 510 (abstr).
29. Juric, D, Munster, P, Campone, M, Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2–) advanced breast cancer (aBC): phase Ib safety, preliminary efficacy and molecular analysis. J Clin Oncol, 34(suppl), 2016, 568 (abstr).
30. Hu, W, Sung, T, Jessen, BA, et al. Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies. Clin Cancer Res 22 (2016), 2000–2008.
31. Cristofanilli, M, Turner, NC, Bondarenko, I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17 (2016), 425–439.
32. Arnedos M, Cheaib B, Bayar AM, et al. Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: the Preoperative Palbociclib (POP) randomized trial. AACR 107th Annual Meeting; New Orleans, LA, USA; April 16–20, 2016. Abstract CT041.
33. Patnaik, A, Rosen, LS, Tolaney, SM, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov 6 (2016), 740–753.
34. Herrera-Abreu, MT, Palafox, M, Asghar, U, et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res 76 (2016), 2301–2313.
35. Sabatini, DM, mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6 (2006), 729–734.
36. Miller, TW, Hennessy, BT, Gonzalez-Angulo, AM, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 120 (2010), 2406–2413.
37. deGraffenried, LA, Friedrichs, WE, Russell, DH, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 10 (2004), 8059–8067.
38. Akcakanat, A, Sahin, A, Shaye, AN, Velasco, MA, Meric-Bernstam, F, Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer 112 (2008), 2352–2358.
39. Boulay, A, Rudloff, J, Ye, J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11 (2005), 5319–5328.
40. Ellard, SL, Clemons, M, Gelmon, KA, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 27 (2009), 4536–4541.
41. Chan, S, Scheulen, ME, Johnston, S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23 (2005), 5314–5322.
42. Awada, A, Cardoso, F, Fontaine, C, et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 44 (2008), 84–91.
43. Fleming, GF, Ma, CX, Huo, D, et al. Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat 136 (2012), 355–363.
44. Carpenter, JC, Roche, H, Capone, M, et al. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol, 23(suppl), 2005, 564.
45. Wolff, AC, Lazar, AA, Bondarenko, I, et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 31 (2013), 195–202.
46. Baselga, J, Semiglazov, V, van Dam, P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27 (2009), 2630–2637.
47. Bachelot, T, Bourgier, C, Cropet, C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30 (2012), 2718–2724.
48. Piccart, M, Hortobagyi, GN, Campone, M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann Oncol 25 (2014), 2357–2362.
49. Carlson, RW, Allred, DC, Anderson, BO, et al. Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10 (2012), 821–829.
50. Cardoso, F, Costa, A, Norton, L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol 25 (2014), 1871–1888.
51. Rugo, HS, Pritchard, KI, Gnant, M, et al. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol 25 (2014), 808–815.
52. Rugo, HS, Chambers, MS, Keating Litton, J, et al. Prevention of stomatitis in patients with hormone receptor–positive advanced breast cancer treated with everolimus plus exemestane: a phase II study of a steroid-based mouthwash. J Clin Oncol, 32(suppl), 2014 5s (abstr TPS661).
53. Hortobagyi, GN, Chen, D, Piccart, M, et al. Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor feceptor 2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol 34 (2015), 419–426.
54. Wagle, N, Grabiner, BC, Van Allen, EM, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov 4 (2014), 546–553.
55. Iyer, G, Hanrahan, AJ, Milowsky, MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science, 338, 2012, 221.
56. Andre, F, Bachelot, T, Commo, F, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 15 (2014), 267–274.
57. Treilleux, I, Arnedos, M, Cropet, C, et al. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. Ann Oncol 26 (2015), 120–125.
58. Loi, S, Michiels, S, Baselga, J, et al. PIK3CA genotype and α PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PLoS One, 8, 2013, e53292.
59. O'Reilly, KE, Rojo, F, She, QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66 (2006), 1500–1508.
60. Di Cosimo, S, Sathyanarayanan, S, Bendell, JC, et al. Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial. Clin Cancer Res 21 (2015), 49–59.
61. Hsieh, AC, Liu, Y, Edlind, MP, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485 (2012), 55–61.
62. Whitman, M, Downes, CP, Keeler, M, Keller, T, Cantley, L, Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 332 (1988), 644–646.
63. Yamamoto, K, Graziani, A, Carpenter, C, Cantley, LC, Lapetina, EG, A novel pathway for the formation of phosphatidylinositol 3, 4-bisphosphate. Phosphorylation of phosphatidylinositol 3-monophosphate by phosphatidylinositol-3-monophosphate 4-kinase. J Biol Chem 265 (1990), 22086–22089.
64. Engelman, JA, Luo, J, Cantley, LC, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7 (2006), 606–619.
65. Vanhaesebroeck, B, Leevers, SJ, Ahmadi, K, et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 70 (2001), 535–602.
66. Beagle, B, Fruman, DA, A lipid kinase cousin cooperates to promote cancer. Cancer Cell 19 (2011), 693–695.
67. Soler, A, Serra, H, Pearce, W, et al. Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. J Exp Med 210 (2013), 1937–1945.
68. Hirsch, E, Ciraolo, E, Franco, I, Ghigo, A, Martini, M, PI3K in cancer–stroma interactions: bad in seed and ugly in soil. Oncogene 33 (2014), 3083–3090.
69. Maehama, T, Dixon, JE, The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273 (1998), 13375–13378.
70. Lehmann, BD, Bauer, JA, Schafer, JM, et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res, 16, 2014, 406.
71. Samuels, Y, Velculescu, VE, Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3 (2004), 1221–1224.
72. Van Keymeulen, A, Lee, MY, Ousset, M, et al. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature 525 (2015), 119–123.
73. Lawson, DA, Bhakta, NR, Kessenbrock, K, et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature 526 (2015), 131–135.
74. Bosch, A, Li, Z, Bergamaschi, A, et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med, 7, 2015, 283ra51.
75. Crowder, RJ, Phommaly, C, Tao, Y, et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 69 (2009), 3955–3962.
76. Maira, SM, Pecchi, S, Huang, A, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 11 (2012), 317–328.
77. Baselga J, Im S-A, Iwata H, et al. PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): first results from the randomized, phase III BELLE-2 trial. San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 8–12, 2015. Abstract S6-01.
78. Bendell, JC, Rodon, J, Burris, HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30 (2012), 282–290.
79. Hong, DS, Bowles, DW, Falchook, GS, et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 18 (2012), 4173–4182.
80. Markman, B, Tabernero, J, Krop, I, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol 23 (2012), 2399–2408.
81. Bowles, DW, Ma, WW, Senzer, N, et al. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer 109 (2013), 1085–1092.
82. Krop I, Johnston S, Mayer IA, Dickler M, et al. The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer—part I results. San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 8–12, 2015. Abstract S2-02.
83. Akinleye, A, Avvaru, P, Furqan, M, Song, YP, Liu, DL, Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol, 6, 2013, 88.
84. Juric, D, Saura, C, Cervantes, A, Baselga, J, Ph1b study of the PI3K inhibitor GDC-0032 in combination with fulvestrant in patients with hormone receptor-positive advanced breast cancer. Cancer Res, 73(suppl), 2013 PD1-3 (abstr).
85. Janku F, Juric D, Cortes J, Baselga J. Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2-locally advanced or metastatic breast cancer. San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 9–13, 2014. Abstract PD5-05.
86. Elkabets, M, Vora, S, Juric, D, et al. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med, 5, 2013, 196ra99.
87. Ilic, N, Utermark, T, Widlund, HR, Roberts, TM, PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci USA 108 (2011), E699–E708.
88. Muranen, T, Selfors, LM, Worster, DT, et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 21 (2012), 227–239.
89. Serra, V, Eichhorn, PJ, Garcia-Garcia, C, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest 123 (2013), 2551–2563.
90. Hyman D, Smyth L, Bedard P, et al. AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors. AACR–NCI–EORTC International Conference on Molecular Targets and Cancer Therapeutics; Boston, MA, USA; Nov 5–9, 2015. Abstract B109.
91. Ross, JS, Gay, LM, Wang, K, et al. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: an emerging opportunity for anti-HER2 targeted therapies. Cancer 22 (2016), 2654–2662.
92. Bose, R, Kavuri, SM, Searleman, AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3 (2013), 224–237.
93. mut MBC). J Clin Oncol, 34(suppl), 2016, 516 (abstr).
94. Desmedt, C, Zoppoli, G, Gundem, G, et al. Genomic characterization of primary invasive lobular breast bancer. J Clin Oncol 34 (2016), 1872–1881.
95. Tutt, A, Robson, M, Garber, JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376 (2010), 235–244.
96. Soria, JC, DeBraud, F, Bahleda, R, et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann Oncol 25 (2014), 2244–2251.
97. Dawson, SJ, Tsui, DW, Murtaza, M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368 (2013), 1199–1209.
98. Yardley, DA, Ismail-Khan, RR, Melichar, B, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 31 (2013), 2128–2135.
99. King, TA, Lyman, JP, Gonen, M, et al. Prognostic impact of 21-gene recurrence score in patients with stage IV breast cancer: TBCRC 013. J Clin Oncol 34 (2016), 2359–2365.
100. Swanton, C, Soria, JC, Bardelli, A, et al. Consensus on precision medicine for metastatic cancers: a report from the MAP conference. Ann Oncol 27 (2016), 1443–1448.
101. Mehta, RS, Barlow, WE, Albain, KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 367 (2012), 435–444.
102. Vora, SR, Juric, D, Kim, N, et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 26 (2014), 136–149.
103. Rugo H, Delord J-P, Im S-A, Ott PA, et al. Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 8–12, 2015. Abstract S5-07.